Practical evaluation and management of cutaneous lymphoma

Journal of the American Academy of Dermatology

Volumn 46, Issue 3, 2002, Pages 325-360

  Fung, Maxwell A ^a   Murphy, Michael J ^a   Hoss, Diane M ^a   Grant Kels, Jane M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; ETRETIN; GAMMA INTERFERON; ISOTRETINOIN; METHOTREXATE; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RETINOID; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CONTACT DERMATITIS; DRUG ERUPTION; DRUG INDUCED DISEASE; ELECTRON BEAM; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LEUKOPENIA; LONGITUDINAL STUDY; MEDICAL SPECIALIST; MICROSCOPY; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SKIN LYMPHOMA; TELANGIECTASIA; ULTRAVIOLET B RADIATION;

EID: 0036124603     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.121355     Document Type: Article

References (251)

1. Management of cutaneous lymphomas using a multidisciplinary approach
2. Cutaneous T-cell lymphoma
3. Interrater and intrarater reliability of histologic criteria in early cutaneous T-cell lymphoma
4. Proceedings of the Second International Symposium on Cutaneous T-cell lymphoma
5. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: An EORTC cutaneous lymphoma project group study
6. Can dermatopathologists reliably make the diagnosis of mycosis fungoides? If not, who can?
7. Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis
8. Detection of monoclonal lymphoid cell populations by polymerase chain reaction technology
9. Detection of expanded T cell clones in skin biopsy samples of patients with lichen sclerosus et atrophicus by T cell receptor-gamma polymerase chain reaction assays
10. Clonal dermatitis: A potential precursor of CTCL with varied clinical manifestations
11. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin
12. EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer
13. Secondary lymph node involvement from primary cutaneous large B-cell lymphoma of the leg: Sentinel lymph nodectomy as a new strategy for staging circumscribed cutaneous lymphomas
14. Cutaneous lymphoma: Understanding the new classification schemes
15. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
16. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: A progress report
17. Benign and malignant cutaneous lymphoproliferative disorders including mycosis fungoides
18. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients
19. Clinical stage 1A (limited patch and plaque) mycosis fungoides: A long-term outcome analysis
20. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients
21. Mycosis fungoides and Sezary syndrome
22. Persistence of human T cell lymphotropic virus type 1 (HTLV-1) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides
23. HTLV-I and CTCL: The link is missing
24. Mycosis fungoides: Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor
25. Mycosis fungoides in relation to environmental exposures and immune response: A case-control study
26. Pityriasis lichenoides-like mycosis fungoides in children
27. Progression of pigmented purpura-like eruptions to mycosis fungoides: Report of three cases
28. Variants of mycosis fungoides and related cutaneous T-cell lymphomas
29. Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: Four cases
30. The patch stage of mycosis fungoides: Criteria for histologic diagnosis
31. Light-microscopic assessment of 100 patients with patch/plaque stage mycosis fungoides
32. The histologic spectrum of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): A review of 222 biopsies, including newly described patterns and the earliest pathologic changes
33. Reassessment of histologic parameters in the diagnosis of mycosis fungoides
34. Early diagnosis of mycosis fungoides: Vacuolar interface dermatitis
35. Efficacy of histologic criteria for diagnosing early mycosis fungoides: An EORTC Cutaneous Lymphoma Study Group investigation
36. The histologic value of adnexal (eccrine gland and follicle) infiltration in mycosis fungoides
37. Atypical cutaneous changes after topical treatment with nitrogen mustard in patients with mycosis fungoides
38. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma
39. Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: A critical reappraisal
40. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: Identification of rapidly progressive and chronic subtypes
41. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: A distinct clinicopathological entity with an aggressive clinical behavior
42. The clinicopathologic spectrum of cytotoxic lymphomas of the skin
43. A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: Further evidence that pagetoid reticulosis is not a variant of mycosis fungoides
44. Phenotypic characterization of skin-infiltrating cells in pagetoid reticulosis by monoclonal antibodies
45. Woringer-Kolopp disease (pagetoid reticulosis): Four cases with histopathologic, ultrastructural, and immunohistologic observations
46. Pagetoid reticulosis (Woringer-Kolopp disease)
47. Mycosis fungoides palmaris et plantaris or acral pagetoid reticulosis?
48. Controversies and discussion on early diagnosis of cutaneous T-cell lymphoma
49. Immunophenotyping and T-cell receptor gamma gene rearrangement analysis as an adjunct to the histopathologic diagnosis of mycosis fungoides
50. CD7 paraffin reactive antibody: Loss of expression in benign and malignant cutaneous lymphocytic infiltrates
51. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: Experience with an antibody reactive with paraffin embedded tissue
52. Mycosis fungoides with CD30-positive cells in the epidermis
53. Detection of TCR-γ gene rearrangements in early mycosis fungoides by nonradioactive PCR-SSCP
54. p16INK4a gene alterations are frequent in lesions of mycosis fungoides
55. Application of DNA flow cytometry from paraffin-embedded tissue to the diagnosis of mycosis fungoides
56. Mycosis fungoides beginning in childhood and adolescence
57. CTCL in patients under 20 years of age: A series of 5 cases
58. Mycosis fungoides with onset before 20 years of age: Review of 24 patients and report of a case diagnosed at age 22 months
59. Mycosis fungoides in young patients: Clinical characteristics and outcome
60. Mycosis fungoides in patients under 20 yeras of age: Report of 7 cases, review of the literature and study of the clinical course
61. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses
62. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma
63. Secondary malignant neoplasms in 71 patients with Sezary syndrome
64. Systemic Hodgkin's lymphoma in a patient with Sezary syndrome
65. Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients
66. Regressing atypical histiocytosis: A cutaneous proliferation of atypical neoplastic histiocytes with unexpectedly indolent biologic behavior
67. Primary cutaneous lymphomas other than mycosis fungoides
68. Relative frequency of various forms of primary cutaneous lymphomas
69. Mycosis fungoides: Evolution towards large-cell lymphoma
70. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin
71. Ki-1-positive anaplastic large-cell lymphoma can mimic benign dermatoses
72. Primary cutaneous Ki-1 (CD30) positive anaplastic large cell lymphoma in childhood
73. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin
74. Analysis of the t(2;5)(p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
75. Solitary primary cutaneous CD30+ large cell lymphoma of natural killer cell phenotype bearing the t(2;5)(p23;q35) translocation and presenting in a child
76. CD56 expression in a case of primary cutaneous CD30+ anaplastic large cell lymphoma
77. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: Clinicopathologic, immunohistochemical, and molecular analyses of seven cases
78. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas
79. Lymphoma- and leukemia-associated cutaneous atypical CD30+ T-cell reactions
80. CD30/Ki-1-positive lymphoproliferative disorders of the skin: Clinicopathologic correlation and statistical analysis of 86 cases. A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group
81. Lymphomatoid papulosis, Ki-1+ lymphoma, and primary cutaneous Hodgkin's disease
82. "Lymphomatoid" pityriasis lichenoides: A variant with histological features simulating lymphoma. A clinical and histopathological study of 15 cases with details of long-term follow-up
83. Lymphomatoid papulosis update: A historical perspective
84. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas
85. Lymphomatoid papulosis
86. Eosinophilic histiocytosis: A variant form of lymphomatoid papulosis or a disease sui generis?
87. Pseudocarcinomatous change in lymphomatoid papulosis and other primary cutaneous CD30 positive lymphoma: A clinicopathological and immunohistochemical study of six patients
88. Is there a special relationship between CD30-positive lymphoproliferative disorders and epidermal proliferation?
89. Lymphomatoid papulosis and cutaneous CD30+ lymphoma
90. Cutaneous lymphomas and leukemias
91. Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like): A distinctive type of cutaneous T-cell lymphoma
92. Angiocentric T cell lymphoma of the skin presenting as inflammatory nodules of the leg
93. CD4+ CD56+ cutaneous neoplasms: A distinct hematological entity?
94. Classification of natural killer cell neoplasms
95. Nasal and nasal type CD56+ natural killer cell/T-cell lymphoma: A case with rapid progression to bone marrow involvement
96. Clinicopathological features of CD56+ nasal-type T/natural killer lymphomas with lobular panniculitis
97. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma
98. Cytophagic histiocytic panniculitis: A critical reappraisal
99. Subcutaneous panniculitic T-cell lymphoma
100. Subcutaneous T-cell lymphoma with associated hemoophagocytic syndrome and terminal leukemic transformation
101. Aggressive cutaneous NK and NK-like T-cell lymphomas: Clinicopathologic, immunohistochemical, and molecular analyses of 12 cases
102. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma
103. Gamma delta T-cell lymphoma of the skin: A clinical, microscopic, and molecular study
104. Variation in the clinical courses of adult T-cell leukemia
105. Acute adult T-cell leukemia/lymphoma presenting with florid cutaneous disease
106. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: A clinical, immunohistological, and molecular analysis
107. Skin lesions in angioimmunoblastic lymphadenopathy: Histological and immunological studies
108. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma
109. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type
110. Heterogeneity of Epstein-Barr virus infection in angioimmunoblastic lymphadenopathy type T-cell lymphoma
111. Primary cutaneous pleomorphic small T-cell lymphoma: A review of 11 cases
112. Lymphoepithelioid cell lymphoma (Lennert's lymphoma): Clinical features derived from analysis of 108 cases
113. Cutaneous involvement in Lennert's lymphoma
114. Lymphoepithelioid lymphoma (Lennert's lymphoma) presenting as atypical granuloma annulare
115. Lennert's lymphoma: A variant of cytotoxic T-cell lymphoma?
116. Lymphoepithelioid lymphoma (Lennert's lymphoma) is a monoclonal proliferation of helper/inducer T cells
117. Primary cutaneous B-cell lymphoma: A clinical, histological, phenotypic and genotypic study of 21 cases
118. Cutaneous immunocytomas: A clinicopathologic study of 26 cases
119. Solid facial edema preceding a diagnosis of retro-orbital B-cell lymphoma
120. Anetoderma arising in cutaneous B-cell lymphoproliferative disease
121. Are primary cutaneous immunocytoma and marginal zone lymphoma the same disease?
122. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: A study of 15 patients
123. Primary cutaneous marginal zone B-cell lymphoma: A report of 9 cases
124. Primary cutaneous marginal zone B-cell lymphoma: A recently described entity of low-grade malignant cutaneous B-cell lymphoma
125. Human herpesvirus 8-specific DNA sequences in primary cutaneous B-cell lymphomas
126. Primary cutaneous B-cell lymphoma with a dermatomal distribution
127. Primary cutaneous large B-cell lymphomas
128. Primary cutaneous large B-cell lymphomas of the legs
129. Evaluation of classic architectural criteria in non-mycosis fungoides cutaneous lymphomas
130. Cutaneous spindle-cell B-cell lymphoma: A morphologic variant of cutaneous large B-cell lymphoma
131. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities
132. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: A clinicopathologic and prognostic study of 42 patients
133. T-cell-rich B-cell lymphoma
134. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
135. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
136. Molecular pathology of posttransplantation lymphoproliferative disorders
137. Mantle-cell lymphomas of the skin
138. Mantle zone lymphoma: An immunohistologic study of skin lesions
139. Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data
140. Lymphoblastic lymphoma presenting in cutaneous sites: A clinicopathologic analysis of six cases
141. Precursor B-cell lymphoblastic lymphoma: A predominantly extranodal tumor with low propensity for leukemic involvement
142. CD56 and terminal deoxynucleotidyl transferase positive cutaneous lymphoblastic lymphoma
143. Angiotropic lymphoma: Proliferation of B cells in the capillaries of cutaneous angiomas
144. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription
145. Hodgkin and Reed-Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: Potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease
146. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease
147. The mode of spread of Hodgkin's disease to the skin
148. Skin involvement in Hodgkin's disease
149. Cutaneous involvement in Hodgkin's disease
150. Hodgkin's disease manifesting as prurigo nodularis
151. Nodular prurigo associated with Hodgkin's disease
152. Adult-onset recalcitrant eczema: A marker of noncutaneous lymphoma or leukemia
153. Cutaneous T-cell lymphoma: Update of treatment
154. Mycosis fungoides and the Sezary syndrome
155. Cutaneous T cell lymphomas
156. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides
157. The treatment of mycosis fungoides: Adjuvant topical mechlorethamine after electron beam therapy
158. Mycosis fungoides: Management with topical nitrogen mustard
159. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas
160. Ointment-based mechlorethamine treatment for mycosis fungoides
161. Local bullous reaction from topical mechlorethamine (mustine)
162. Urticaria and anaphylactoid reactions after topical application of mechlorethamine
163. Stevens-Johnson syndrome associated with topical nitrogen mustard therapy
164. Topical carmustine (BCNU) for cutaneous T cell lymphoma: A 15-year experience in 143 patients
165. Allergic contact dermatitis from topical carmustine
166. Topical carmustine (BCNU) for patch/plaque mycosis fungoides
167. Mechlorethamine hydrochloride solutions and ointment: Prolonged stability and biological activity
168. Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing
169. Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream
170. Fluocinolone acetonide 0.2% cream: A co-operative clinical trial
171. Topical corticosteroids for mycosis fungoides
172. The benefits of topical bexarotene (Targretin) in patients with refractory or persistent early stage CTCL
173. Phase I-II trial of Targretin gel in the topical treatment of patients with cutaneous T-cell lymphoma
174. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma
175. Narrowband (311-nm) UV-B therapy for small-plaque parapsoriasis and early-stage mycosis fungoides
176. Narrowband TL-101 phototherapy for patch-stage mycosis fungoides
177. Ultraviolet A1 (340-400nm) phototherapy for cutaneous T-cell lymphoma
178. "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides
179. Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up
180. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: Preliminary results
181. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy
182. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alpha: A 10-year experience at a single institution
183. Extracorporeal photopheresis in Sezary syndrome
184. Sezary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis
185. Effectiveness of photopheresis in Sezary syndrome
186. Total skin electron beam therapy in the management of mycosis fungoides
187. Once weekly total-skin electron-beam therapy for mycosis fungoides: 7 Years' experience
188. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides
189. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides
190. Intralesional interferon in the treatment of early mycosis fungoides
191. Interferon treatment of cutaneous T-cell lymphoma
192. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa
193. Granulomatous slack skin: Successful treatment with recombinant interferon-gamma
194. Alternating recombinant and natural alpha-interferon helps to prevent clinical resistance to interferon in cutaneous T-cell lymphoma treatment
195. Interferon-alpha-associated development of bullous lesions in mycosis fungoides
196. Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL
197. Oral bexarotene benefits patients with refractory advanced stage CTCL
198. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)
199. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol
200. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage: A report from the Scandinavian Mycosis Fungoides Group
201. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides
202. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome)
203. Low-dose methotrexate for the Sezary syndrome
204. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders
205. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma
206. Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides
207. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients
208. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
209. The treatment of Sezary syndrome
210. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy
211. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma
212. Subcutaneous T-cell lymphoma treated with systemic chemotherapy, autologous stem cell support, and limb amputation
213. Aggressive subcutaneous panniculitis-like T-cell lymphoma: Complete remission with fludarabine, mitoxantrone and dexamethasone
214. Angiocentric T-cell lymphoma of the skin: An aggressive lymphoma distinct from mycosis fungoides
215. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features
216. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II
217. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma
218. Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma
219. Combination treatment with extracorporeal photopheresis, interferon alpha and interleukin-2 in a patient with the Sezary syndrome
220. Hemolytic-uremic syndrome induced by pentostatin in a patient with cutaneous T-cell lymphoma
221. Systemic administration of Hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang), a Japanese-Chinese herbal medicine, maintains interferon-γ production by peripheral blood mononuclear cells in patients with mycosis fungoides
222. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
223. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma
224. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody
225. Tumor-specific peptides in cutaneous T-cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor
226. Recurrence with histological transformation 40 days after autologous peripheral blood stem cell transplantation (APB-SCT) for cutaneous CD30-negative large T cell lymphoma
227. Intralesional cisplatin for the treatment of cutaneous B-cell lymphoma
228. Rituximab in cutaneous B-cell lymphoma: A report of two cases
229. Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis
230. The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States
231. Risk of second malignancy after cutaneous T-cell lymphoma
232. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma
233. Cutaneous T-cell lymphoma: Clinicopathological relationships, therapy and survival in ninety-two patients
234. Mycosis fungoides: Response to therapy and survival patterns in 85 cases
235. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome
236. Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome
237. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides
238. Peripheral blood T cell clonality in mycosis fungoides: An independent prognostic marker?
239. Infections complicating mycosis fungoides and Sezary syndrome
240. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma
241. Report of the committee on staging and classification of cutaneous T-cell lymphomas
242. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma
243. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids
244. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate
245. Combination chemotherapy with bleomycin, cyclophosphamide, prednisone, and etretinate (BCPE) in advanced mycosis fungoides: A six-year experience
246. Combined modality therapy for cutaneous T-cell lymphoma
247. Combined modality therapy for tumor stage mycosis fungoides: Results of a 10-year follow-up
248. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides